Drugs / CAT-2054
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02374047 | Jan → Jul 2015 | hyperlipidemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02608697 | Oct 2015 → May 2016 | hyperlipidemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAT-2054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02374047 ↗ |
| Known as | CAT-2054-C | “CAT-2054 will be administered either as an uncoated capsule (CAT-2054) or a coated capsule (CAT-2054-C).” NCT02374047 ↗ |